Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.56 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171975 | 0.83 | — | — | |
| SCHEMBL29794327 | 0.83 | — | — | |
| SCHEMBL17051516 | 0.82 | HPGDS (0.54) | HPGDS | |
| SCHEMBL15937427 | 0.82 | KDM4E (0.51) | CYP11B2ALDH1A1CYP2A6KDM1AGAA | |
| SCHEMBL13683832 | 0.82 | CYP11B2 (0.48) | CYP11B2KIF11MMP3ALDH1A1CYP2A6 | |
| SCHEMBL11753523 | 0.82 | CYP11B2 (0.48) | CYP11B2KIF11MMP3ALDH1A1CYP2A6 | |
| Hydrochloric Acid SCHEMBL8845303 | 0.81 | ALDH1A1 (0.53) | CYP11B2ALDH1A1CYP2A6GAAKDM4E | |
| Hydrochloric Acid SCHEMBL4432024 | 0.81 | ALDH1A1 (0.53) | CYP11B2ALDH1A1CYP2A6GAAKDM4E | |
| SCHEMBL3266198 | 0.80 | CLK4 (0.53) | CYP11B2ALDH1A1CYP1A2 | |
| SCHEMBL17324161 | 0.80 | EGLN2 (0.43) | HPGDSEGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200274070-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | SHANGHAI NICHEM FINE CHEMICAL CO., LTD. (CN) | 2020-08-27 | — | — | US | disclosed |
| US-10312459-B2 | Compound and organic electronic device using the same | NICHEM FINE TECHNOLOGY CO., LTD. (TW) | 2019-06-04 | — | — | US | disclosed |
| EP-2799516-B1 | LIQUID CRYSTAL MATERIAL OF SMECTIC PHASE IN HIGH SCATTERING STATE AND DISPLAY DEVICE THEREOF | HALATION PHOTONICS CORP (CN) | 2019-02-20 | — | — | EP | disclosed |
| US-20170213978-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | NICHEM FINE TECHNOLOGY CO., LTD. (TW) | 2017-07-27 | — | — | US | disclosed |
| US-9655363-B2 | Microbiocides | SYNGENTA PARTICIPATIONS AG (CH) | 2017-05-23 | — | — | US | disclosed |
| US-9655363-B2 | Microbiocides | SYNGENTA PARTICIPATIONS AG (CH) | 2017-05-23 | — | — | US | disclosed |
| EP-2951167-B1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-01-25 | — | — | EP | disclosed |
| US-20150351402-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-12-10 | — | — | US | disclosed |
| US-20150351402-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-12-10 | — | — | US | disclosed |
| US-8912218-B2 | Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-12-16 | — | — | US | disclosed |
| WO-2014118170-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-08-07 | — | — | WO | disclosed |
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
| EP-1633735-B1 | DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES, PREPARATION METHODS THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI SA (FR) | 2011-11-30 | — | — | EP | disclosed |
| US-8034818-B2 | Therapeutic uses of derivatives of piperidinyl- and piperazinyl-alkyl carbamates | SANOFI-AVENTIS (FR) | 2011-10-11 | — | — | US | disclosed |
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-09-01 | — | — | US | disclosed |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | US | disclosed |
| US-7214798-B2 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MET, ALK, REL | CYP11B2 215/4885KIF11 3248/4885MMP3 2009/4885 |
| US-20170213978-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | OR51E2, OR10J3, ESR1 | CYP11B2 283/4885KIF11 2083/4885MMP3 4690/4885 |
| US-10312459-B2 | Compound and organic electronic device using the same | OR51E2, OR10J3, ESR1 | CYP11B2 283/4885KIF11 2083/4885MMP3 4690/4885 |
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP11B2 1039/4885KIF11 2635/4885MMP3 1271/4885 |
| US-20200274070-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | ESR1, CCNA1, CCNE2 | CYP11B2 266/4885KIF11 2228/4885MMP3 4469/4885 |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3, H1-2 | CYP11B2 656/4885KIF11 3374/4885MMP3 2243/4885 |
| US-20150351402-A1 | NOVEL MICROBIOCIDES | MSR1, C1R, CD14 | CYP11B2 1171/4885KIF11 4621/4885MMP3 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.